Introduction
============

In the 2015 World Health Organization report, the percentage of people living with chronic hepatitis B infections was 3.5% (257 million persons) of the global population; it is estimated that fewer than 1.7 million (8%) of the infected patients received anti-viral treatment (WHO, 2017). Of the adult patients living with chronic hepatitis B (CHB) infections, 20%--30% have been estimated to develop cirrhosis or hepatocellular carcinoma (HCC) in the future, and on average, there were 340,000 annual deaths from hepatitis B-induced HCC between 1990 and 2010 (Lozano et al., 2012; WHO, 2019). A variety of genetic factors and viral markers have been used to screen for HBV-related HCC.

###### 

Search Terms

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Concepts       Search terms                                                                                   Search details
  -------------- ---------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population     1.Chronic hepatitis B (MeSH)                                                                   \"hepatitis b, chronic\"\[MeSH Terms\]

                 2\. Chronic hepatitis B infection (KW)                                                         \"Chronic HBV infection\"\[All Fields\]

                 Combine 1, 2 with "OR"                                                                         \"hepatitis b, chronic\"\[MeSH Terms\] OR \"Chronic HBV infection\"\[All Fields\]

  Index test     3\. Hepatitis B surface antigen (MeSH)                                                         \"hepatitis b surface antigens\"\[MeSH Terms\]

                 4\. Quantification of Hepatitis B surface antigen (KW)                                         Quantification\[All Fields\] AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hepatitis b surface antigen\"\[All Fields\])

                 5\. HBsAg (KW)                                                                                 \"HBsAg\"\[All Fields\]

                 6\. Quantitative serum HBsAg level (KW)                                                        Quantitative\[All Fields\] AND (\"serum\"\[MeSH Terms\] OR \"serum\"\[All Fields\]) AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hbsag\"\[All Fields\]) AND level\[All Fields\]

                 7\. Quantitative Hepatitis B surface antigen (KW)                                              \"Quantitative Hepatitis B surface antigen\"\[All Fields\]

                 8\. HBsAg quantification (KW)                                                                  \"HBsAg quantification\"\[All Fields\]

                 9\. qHBsAg (KW)                                                                                \"qHBsAg\"\[All Fields\]

                 Combine 3, 4, 5, 6, 7, 8, 9 with "OR"                                                          \"qHBsAg\"\[All Fields\] OR (((((\"hepatitis b surface antigens\"\[MeSH Terms\] OR (Quantification\[All Fields\] AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hepatitis b surface antigen\"\[All Fields\]))) OR \"HBsAg\"\[All Fields\]) OR (Quantitative\[All Fields\] AND (\"serum\"\[MeSH Terms\] OR \"serum\"\[All Fields\]) AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hbsag\"\[All Fields\]) AND level\[All Fields\])) OR \"Quantitative Hepatitis B surface antigen\"\[All Fields\]) OR \"HBsAg quantification\"\[All Fields\])

  Outcome        10\. Liver neoplasm (MeSH)                                                                     \"carcinoma, hepatocellular\"\[MeSH Terms\]

                 11\. Liver neoplasm (MeSH)                                                                     \"liver neoplasms\"\[MeSH Terms\]

                 12\. Liver cancer (KW)                                                                         \"Liver cancer\"\[All Fields\]

                 13\. Hepatoma (KW)                                                                             \"Hepatoma\"\[All Fields\]

                 14\. Hepatic cancer (KW)                                                                       \"Hepatic cancer\"\[All Fields\]

                 15\. Malignant hepatic tumor (KW)                                                              \"Malignant hepatic tumor\"\[All Fields\]

                 16\. Hepatic neoplasm (KW)                                                                     \"hepatic neoplasm\"\[All Fields\]

                 17\. HBV-related hepatocarcinogenesis (KW)                                                     \"HBV-related hepatocarcinogenesis\"\[All Fields\]

                 18\. Liver carcinogenesis (KW)                                                                 \"Liver carcinogenesis\"\[All Fields\]

                 Combine 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 with "OR"                                       (((((((\"carcinoma, hepatocellular\"\[MeSH Terms\] OR \"liver neoplasms\"\[MeSH Terms\]) OR \"Liver cancer\"\[All Fields\]) OR \"Hepatoma\"\[All Fields\]) OR \"Hepatic cancer\"\[All Fields\]) OR \"Malignant hepatic tumor\"\[All Fields\]) OR \"hepatic neoplasm\"\[All Fields\]) OR \"HBV-related hepatocarcinogenesis\"\[All Fields\]) OR \"Liver carcinogenesis\"\[All Fields\]

  Final Search   Combine "population", "index test", "outcome" with "AND"\                                      ((\"qHBsAg\"\[All Fields\] OR (((((\"hepatitis b surface antigens\"\[MeSH Terms\] OR (Quantification\[All Fields\] AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hepatitis b surface antigen\"\[All Fields\]))) OR \"HBsAg\"\[All Fields\]) OR (Quantitative\[All Fields\] AND (\"serum\"\[MeSH Terms\] OR \"serum\"\[All Fields\]) AND (\"hepatitis b surface antigens\"\[MeSH Terms\] OR \"hepatitis b surface antigens\"\[All Fields\] OR \"hbsag\"\[All Fields\]) AND level\[All Fields\])) OR \"Quantitative Hepatitis B surface antigen\"\[All Fields\]) OR \"HBsAg quantification\"\[All Fields\])) AND ((((((((\"carcinoma, hepatocellular\"\[MeSH Terms\] OR \"liver neoplasms\"\[MeSH Terms\]) OR \"Liver cancer\"\[All Fields\]) OR \"Hepatoma\"\[All Fields\]) OR \"Hepatic cancer\"\[All Fields\]) OR \"Malignant hepatic tumor\"\[All Fields\]) OR \"hepatic neoplasm\"\[All Fields\]) OR \"HBV-related hepatocarcinogenesis\"\[All Fields\]) OR \"Liver carcinogenesis\"\[All Fields\])) AND (\"hepatitis b, chronic\"\[MeSH Terms\] OR \"Chronic HBV infection\"\[All Fields\]) AND ((\"2002/01/01\"\[PDAT\] : \"2017/12/31\"\[PDAT\]) AND \"humans\"\[MeSH Terms\] AND English\[lang\])
                 Filters: studies published in the last ten years, written in English, and human studies only   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of 10 Selected Studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (author, year)               Liu                         Chien                Lee                     Lee                  Tseng                  Yang                          Ahn                     Kawanawa               Tseng                  Liu
  ---------------------------------- --------------------------- -------------------- ----------------------- -------------------- ---------------------- ----------------------------- ----------------------- ---------------------- ---------------------- ----------------
                                     2016                        2016                 2015                    2013                 2012                   2017                          2015                    2014                   2017                   2017

  Country                            Taiwan                      Taiwan               Taiwan                  Taiwan               Taiwan                 China                         Korea                   Japan                  Taiwan                 Taiwan

  Setting of data collection         Community                   Community            Hospital                Community            Hospital               Community                     Hospital                Hospital               Hospital               Community

  Study design                       Retrospective cohort        Prospective cohort   Cross-sectional         Prospective cohort   Retrospective cohort   Case-control                  Retrospective cohort    Prospective cohort     Retrospective cohort   Case-control

  Sample size (n)                    1529                        301                  412                     3340                 2688                   432                           527                     167                    2075                   1070

  Age (years)                        Mean age: 46.6              \< 40: 22 (7.3%)\    Mean ± SD: 68.6 ± 6.9   \< 40: 1147\         \< 40: 1407\           Case group: 56.37 ± 9.24\     Mean ± SD: 48.8 ± 9.9   Mean ± SD:\            \< 40: 1076\           Mean age: 58.7
                                                                 ≥ 40: 279 (92.7%)                            ≥ 40: 2193           ≥ 40: 1281             Control group: 58.12 ± 9.18                           49.2 ± 11.1            ≥ 40: 999              

  Gender                                                                                                                                                                                                                                                      

  Male/Female                        993/536                     240/61               262/150                 2030/1310            1634/1054              317/115                       311/216                 112/55                 1222/853               794/276

  HBV genotype (n)                   B: 775\                     B: 128\              NA                      C: 718\              B: 1308\               NA                            NA                      A: 3\                  B: 1612\               NA
                                     B + C/C: 754                C: 125\                                      B or B + C: 1480     C: 312                                                                       B: 4\                  C: 371\                
                                                                 B + C: 2                                                                                                                                       C: 144\                Undetermined: 92       
                                                                                                                                                                                                                Undetermined: 16                              

  Stage of CHB (n)                   Inactive CHB: 77\           Unknown: 301         Unknown: 412            Unknown: 3340        Inactive CHB: 2688     Unknown: 432                  Unknown: 527            Unknown: 167           Inactive CHB: 2075     Unknown: 1070
                                     Immune reactivation: 497\                                                                                                                                                                                                
                                     Unknown: 752                                                                                                                                                                                                             

  ALT mean/median, SD/ranges (U/L)   NA                          NA                   105.4 ± 252.7           NA                   NA                     NA                            37 (24--66)             NA                     NA                     NA

  Qualitative HBeAg Positive/\       0/1529                      83/215               15/307                  504/2836             523/2165               93/339                        0/527                   81/86                  372/1703               NR/NR
  negative (n/n)                                                                                                                                                                                                                                              

  HBV DNA (IU/ml)                                                                                                                                                                                                                                             

  \< 2,000 (n)                       980                         97                   72                      1899                 1068                   220                           0                       NA                     876                    389

  ≥ 2,000 (n)                        549                         204                  144                     1441                 1097                   212                           527                     NA                     1703                   681

  HIV coinfection (n)                NA                          NA                   NA                      NA                   NA                     NA                            NA                      NA                     NA                     NA

  HCV coinfection, Yes/No (n/n)      0/1529                      NA/NA                0/412                   0/3340               0/2688                 NA/NA                         NA/NA                   NA/NA                  0/2075                 NA/NA

  Treatment received/\               No/NA                       No/NA                No/NA                   No/NA                No/NA                  Unknown/NR                    No/NA                   Yes/\                  No/NA                  No/NA
  Medications                                                                                                                                                                                                   Nucleotide analogues                          

  Duration of follow-up (years)      12                          12                   Mean ± SD:\             12                   Mean ± SD:\            † Case group: 4.42\           Median (ranges):\       Median (ranges):\      Mean ± SD:\            NR
                                                                                      7.1 ± 6.3                                    14.7 ± 4.3             † Control group: 9.53         3.6 (0.5--5.8)          5.8 (2--13.1)          16.02 ± 4.75           

  HBsAg cut-off\                     1000                        100\                 100                     100\                 100\                   100\                          1000                    2000                   1000                   100\
  value (IU/ml)                                                  1000                                         1000                 1000                   1000                                                                                                1000
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

†, Median age in the case and the control group; NA, not applicable; NR, not reported; SD, standard deviation; n, number; HBV, hepatitis B virus; CHB, chronic hepatitis B; ALT, alanine aminotransferase; HBeAg, hepatitis B e-antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid; HIV, human immunodeficiency virus; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen
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The presence of hepatitis B surface antigen (HBsAg) is the primary indicator for confirming HBV infection. The presence of HBsAg has shown a strong association with that of the covalently closed circular deoxyribonucleic acid (cccDNA) that functions as a model for transcription of all viral ribonucleic acids (RNAs) and greatly correlates with the viral load (Werle-Lapostolle et al., 2004). The formation of cccDNA is the key mechanism of HBV tumourigenesis, but measuring cccDNA levels remains challenging. As a result, HBsAg quantification has become a commonly used proxy (Werle-Lapostolle et al., 2004; Guo and Guo, 2015; Valaydon and Locarnini, 2017). In a systematic review involving 6,028 patients with CHB published in 2015, 335 of them contracted HCC during the 14.7-year follow-up, and the risk of HCC in patients with high serum HBsAg levels (≥1,000 IU/ml) was greater than that among patients with low HBsAg levels (Qu et al., 2015).

Although new clinical research has focussed on the effect of the quantitation of HBsAg on the prediction of HCC development in different populations, stages, and cut-off values, no results have been applied to establish routine practices yet (Lee et al., 2015; Chien et al., 2016; Liu et al., 2016; Yang et al., 2016; Kumar et al., 2017). We have perceived an increase in the number of publications of HBsAg on HCC, and thus decided to analyse their data to try to obtain a better-estimated measure of the association between HBsAg levels and HCC. We also investigated different cut-off values of the HBsAg level used as a biomarker for HCC development in patients living with chronic hepatitis B infections.

Materials and Methods
=====================

We performed a systematic review and meta-analysis based on our priori protocol registered at PROSPERO (registration number CRD42018081138). The protocol was approved of exemption by the Institutional Review Board of the Faculty of Tropical Medicine, Mahidol University, Thailand (MUTM-EXMPT 2017-006).

*Search strategy and eligibility criteria*

We searched for published articles from January 2002 to November 2017 on PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and ProQuest. Our search terms included chronic hepatitis B infection, HBsAg and HCC. We supplemented our search by reviewing reference lists for all appropriate studies ([Table 1](#T1){ref-type="table"}).

Our eligibility criteria for studies included: (a) various designs (cohort, case-control and cross-sectional studies or randomised trials); (b) participants presenting chronic hepatitis B infections and no limitations regarding age, country, or clinical setting; (c) available values for quantitative HBsAg tests at baseline; (d) newly developed HCC confirmed by standard criteria; (e) English language and (f) possibility of contacting authors for missing data.

*Study selection process*

A researcher (TTV) screened titles and abstracts. Selected full-text articles were analysed to determine their eligibility criteria fit. Then, we searched for missing information from study authors to handle eligibility criteria-related problems. We documented all the reasons for excluding articles.

*Data collection process and quality assessment*

Two independent reviewers (KP and TTV) extracted data and filled out the data extraction forms. Any controversies between the two reviewers were resolved via discussion, or by getting a third opinion (from CK). The review authors independently evaluated the methodological quality of the studies by using the Quality Assessment of Diagnostic Accuracy Studies version-2 tool (QUADAS-2) (Whiting et al., 2011).

*Data analysis*

We analysed the data for the two cut-off points of HBsAg levels: 100 and 1,000 IU/ml. The HBsAg level effect is presented as ORs with 95% confidence interval (CI). We performed an inverse variance meta-analysis to combine effects across studies. We considered an overall OR as statistically significant using a z-test when the P-value \< 0.05. We assessed heterogeneity using Cochrane's Q test with a significance level p \< 0.05 and with an I^2^ test. The I^2^ statistic had three ranges of I^2^ values: low (25%), moderate (50%) and high (75%). We applied fixed effects meta-analysis when there was no evidence of heterogeneity across study effects; otherwise, we applied random effects meta-analysis. In addition, we explored the sources of heterogeneity through subgroup meta-analyses when relevant. Egger's test was used to assess publication bias at a significant threshold of 0.05. We used the Review Manager 5.3 to perform meta-analyses and R version 3.4.2 to draw funnel plots and perform Egger's tests.

Results
=======

*Study selection*

We ran our search using the four databases PubMed, Scopus, CENTRAL and ProQuest. We found 594 articles after eliminating duplicates. After the first round of scanning articles by assessing the titles and abstracts, we included 33 in the second round. We contacted the authors from four studies with initial insufficient data for our analysis and obtained the requested data from 3 studies that were included in the analysis. Of the 33 studies, 10 were relevant to our systematic review and meta-analysis ([Figure 1](#F1){ref-type="fig"}) (Tseng et al., 2012; Lee et al., 2013; Kawanaka et al., 2014; Ahn et al., 2015; Lee et al., 2015; Chien et al., 2016; Liu et al., 2016; Liu et al., 2017; Tseng et al., 2017; Yang et al., 2017).

*Characteristics of 10 included studies*

Characteristics of each primary study are shown in [Table 2](#T2){ref-type="table"}. The total number of patients enrolled in the 10 studies was 12 541, with sample sizes ranging from 167 to 3,340. All of the studies were conducted in Asia (70% in Taiwan). None of the participants from 10 studies presented HIV co-infections. Half of the studies were performed in hospitals and half in communities. Only one study, had participants receiving nucleotide analogue treatments before the start of the study (Kawanaka et al., 2014).

*Methodology assessments*

The risk of bias and applicability concerns of the 10 selected studies is displayed in [Figure 2](#F2){ref-type="fig"}. Most studies presented a low risk of bias respecting patient selection and HBsAg level testing. Thirty percent of studies were at a high risk of bias in terms of HCC diagnosis. The risk of bias in most studies (60%) had to do with flow and timing. All of the studies had low applicability risks, except for the standard reference test, i.e. HCC diagnosis was done for participants with suspected HCC via different screening methods, such as serum alpha-fetoprotein (AFP) and abdominal ultrasound.

[Figure 3](#F3){ref-type="fig"} illustrates the risks of bias and applicability across individual studies. The methodological qualities of the two studies by Chien et al published in 2016 and by Lee et al published in 2015 were the highest (Lee et al., 2015; Chien et al., 2016). We found one study had risks of reference standard, bias, flow and timing and applicability of findings (Yang et al., 2017).

*Association between the baseline level of HBsAg (at 100 IU/ml) and the risk of HCC in patients with chronic hepatitis B infection*

There were six studies investigating the correlation between the baseline HBsAg level and the HCC risk in patients with chronic HBV infection using the HBsAg threshold of 100 IU/ml (Tseng et al., 2012; Lee et al., 2013; Lee et al., 2015; Chien et al., 2016; Liu et al., 2017; Yang et al., 2017). Among 8,223 participants, 1,058 presented HCC during the follow-ups (923 participants with high HBsAg and 135 with low HBsAg levels). We detected a high heterogeneity of ORs among these studies (χ^2^ = 23.72, p = 0.0002, I^2^ = 79%) ([Figure 4](#F4){ref-type="fig"}). Under a random effects model, the patients with high HBsAg level had a 4.99 times higher chance of developing HCC than those with a low HBsAg level (OR = 4.99; 95% CI, 3.01--8.29; p \< 0.00001).

Factors that could potentially cause heterogeneity of ORs across studies included gender, advanced age, HCV coinfection, HBV genotype C and data collection setting. Using the data available, we further explored the sources of heterogeneity by performing a subgroup analysis at the HBsAg threshold of 100 IU/ml: the association between the baseline HBsAg level and the risk of HCC development in studies conducted in the hospitals or in the communities. We found no difference between the hospital setting and the community setting subgroups (χ^2^ = 0, p = 0.95).

*Association between baseline level of HBsAg (at 1000 IU/ml) and risk of HCC*

We analysed data from eight studies reporting on the HBsAg level at 1,000 on the risk of HCC in patients with chronic HBV infection (Tseng et al., 2012; Lee et al., 2013; Ahn et al., 2015; Chien et al., 2016; Liu et al., 2016; Liu et al., 2017; Tseng et al., 2017; Yang et al., 2017). A total of 1,840 patients presented HCC, and among them, 75.5% (1,390) had high HBsAg levels and 24.5% (450) had low HBsAg levels. We observed low heterogeneity (χ^2^ = 14.07, p = 0.05, I^2^ = 50%). Using a fixed effect model, participants with high HBsAg levels had a 2.46-fold rise in the risk of HCC development compared with those who had low levels (OR = 2.46; 95% CI, 2.15--2.83; P \< 0.00001) ([Figure 5](#F5){ref-type="fig"}).

*Association between gender and risk of HCC in patients with chronic HBV infection*

We were able to combine data from seven studies to obtain a summary OR (Tseng et al., 2012; Lee et al., 2013; Kawanaka et al., 2014; Chien et al., 2016; Liu et al., 2017; Tseng et al., 2017; Yang et al., 2017). Our results showed that men had a higher risk of developing HCC than women (OR, 2.12; 95% CI, 1.52--2.95; p \< 0.00001), with moderate heterogeneity (χ^2^ = 20.48, p = 0.002, I^2^ = 71%).

*Association between hepatitis B e-antigen (HBeAg) status and HCC risk*

We found accessible data for six studies (Tseng et al., 2012; Lee et al., 2013; Kawanaka et al., 2014; Chien et al., 2016; Tseng et al., 2017; Yang et al., 2017). Pooled data on the risk of developing HCC among participants with HBeAg positivity compared with the risk in those with HBeAg negativity identified HBeAg positivity as a risk factor for HCC development (OR = 2.99; 95% CI, 1.3--6.89; p = 0.01), with significant heterogeneity (χ^2^ = 99.76, p \< 0.00001, I^2^ = 95%).

*Association between the HBV DNA level and risk of HCC*

We analysed data from seven studies reporting on the difference in HBV DNA levels and the risk of HBV-related HCC (Tseng et al., 2012; Lee et al., 2013; Chien et al., 2016; Liu et al., 2016; Liu et al., 2017; Tseng et al., 2017; Yang et al., 2017). Our results showed that participants with HBV DNA levels ≥ 2000 IU/ml had a 4.37 times higher risk of developing HCC than those with lower HBV DNA level (OR, 4.37; 95% CI, 2.96--6.46; p \< 0.00001), with high heterogeneity (χ^2^ = 33.32, p \< 0.00001, I^2^ = 82%).

*Publication bias*

We visualised publication bias using a funnel plot with six studies included under the cut-off of 100 IU/ml ([Figure 6](#F6){ref-type="fig"}) and eight studies under the cut-off of 1,000 IU/ml ([Figure 7](#F7){ref-type="fig"}). Using Egger's test, we saw no evidence of publication bias (p = 0.4423 for the HBsAg cut-off of 100 IU/ml; p = 0.3647 for the HBsAg cut-off of 1,000 IU/ml).

Discussion
==========

We searched four databases to identify articles published during the past 15 years (January 2002 to November 2017) that fit our eligibility criteria. We selected 10 studies for our review. Most of the populations included in the study were classified as inactive HBV infections and had not received antiviral therapy. Qu et al., (2015) have published a meta-analysis on the effect of serum HBsAg levels for predicting clinical outcomes of patients with chronic HBV infection, but only two studies in their analysis had the baseline HBsAg levels, and they only evaluated the cut-off at 1,000 IU/ml. In our systematic review, we updated and assessed the association with HCC development across the two different available cut-offs (100 and 1,000 IU/ml).

We designed a well-prepared analysis in which we extracted data from the original studies with different HBsAg cut-off points when available; we also combined ORs across studies at each cut-off. Moreover, learning from the previous meta-analysis, we increased the number of research databases (PubMed, Scopus, CENTRAL and ProQuest) to avoid heterogeneity and publication bias.

Our results showed that at the HBsAg cut-off of 100 IU/ml, the odds ratio of developing HCC among patients with chronic HBV infection with an HBsAg level ≥ 100 is 4.99 times that compared with patients with an HBsAg level \< 100, but the heterogeneity is high. In a study by Lee and colleagues, the percentage of elderly participants developing HCC during the follow-up was lower in those with an HBsAg level \< 100 IU/ml at baseline (OR = 1.83; 95% CI, 1.00--3.33), which results in a 63% reduction in the chance of developing HCC in comparison to our results (OR = 4.99; 95% CI, 3.01--8.29) (Lee et al., 2015). However, in our analysis of this cut-off at 100 IU/ml, we found high heterogeneity. To evaluate this finding, we compared one group with studies performed in the hospital to the other group with studies in the community, but we found no difference. We believe the advanced age in the patients in Lee's study, may explain the difference in the chance of developing HCC, but data on age were unavailable to compute this subgroup.

We also found that at the cut-off of 1,000 IU/ml, the patients with an HBsAg ≥ 1,000 IU/ml have a 2.46-fold increased OR of developing HCC (95% CI, 2.15--2.83), which is slightly higher than the published OR of 2.21 (95% CI, 1.52--3.22) (Qu et al., 2015). However, our more recent data were obtained from eight studies with a total of 11,962 samples, which is considerably higher than the number in the review by Qu et al; therefore our study should provide a more precise overall OR for this threshold. In addition, we did not found evidence of publication bias.

Variables such as male gender, HBeAg positivity and high hepatitis B viral load were significantly associated with HCC development, with moderate-to-high heterogeneity. We also observed one study using an HBsAg cut-off of 2,000 IU/ml, and while we did not include that data in our meta-analysis, the study showed that levels of HBsAg ≥2,000 IU/mL were not associated with HCC development (p = 0.64) after receiving long-term anti-viral therapy (Kawanaka et al., 2014). Our results on the well-established factors, namely, male gender, HBeAg positivity and a high HBVDNA level (≥ 2,000 IU/ml) are consistent with earlier findings (Yang et al., 2002; Chen et al., 2006; Poh et al., 2015; Zheng et al., 2017). However, these results should be regarded with some degree of scepticism due to the moderate-to-high variations among studies.

We acknowledge some limitations to our meta-analysis. First, we lacked data on some confounding factors such as the HBV genotypes (genotypes B and C account for most patients in Asia), the HBV stages, age, duration of follow-up, qualitative HBeAg and fibrosis stages, because most included publications in our review studied patients with an unknown stage of liver cirrhosis attributed to a high rate of HCC (Fernandez-Rodriguez and Gutierrez-Garcia, 2014). This made it difficult to explore the heterogeneity of aetiologies. Second, a verification bias was introduced in these chosen studies as participants underwent a gold standard for HCC diagnosis (e.g. histology or two typical imaging findings) once HCC manifestations had been identified during the clinical follow-up. We could omit some HCC cases, bringing about a low incidence of diagnosed HCC outcomes.

In conclusion, without publication bias evidences, the meta-analyses at both HBsAg cut-offs 100 IU/ml and 1,000 IU/ml are associated with an increased risk of HCC development. In addition, risk factors such as male gender, HBeAg positivity and high HBV DNA level have been correlated with a greater risk of HCC development. Therefore, our results may help physicians customize a better HCC surveillance system among patients with chronic HBV infection. Finally, our meta-analysis suggests a need for studies on the value of the HBsAg levels in subgroup populations, especially in those with advanced age, different stages of chronic HBV infection and different HBV genotypes.
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